The primary therapeutic targets for the management of patients with CKD are generally considered to be inhibition of Ang II production with ACE inhibitors (ACEIs) or inhibition of Ang II signaling with angiotensin II type 1 receptor blockers (ARBs) [23]. Here, ACE is linked to chronic kidney disease.